Certain genes might make some people more prone to experience the placebo effect

Researchers are beginning to explore whether the genetics of patients who experience a placebo effect are different from those of patients who don't. It's well known that people can feel better if they believe they are receiving treatment, but the biological pathways involved are relatively unexplored. In a new review, publishing in Trends in Molecular Medicine, scientists at Beth Israel Deaconess Medical Center discuss what we know as well as possible ethical issues related to conducting genetic tests to determine whether a patient is a placebo responder.

"Understanding the placebome - the collection of genes related to placebo responses - opens possibilities to improving patients' responses to clinical care and pharmaceuticals and to refining research designs for detecting drug-placebo differences," says lead author Kathryn Hall, PhD, a member of Beth Israel Deaconess Medical Center's Program in Placebo Studies.

Past studies have revealed that certain signaling pathways in the brain - especially the dopamine, opioid, endocannabinoid, and serotonin pathways - help mediate the placebo effect. Hall and her colleagues examined evidence that genetic variations in these pathways can modify the placebo effect; their findings raise the possibility of using genetic screens to identify placebo responders. Such information could lead to better patient selection for clinical trials - for example by pointing to those who should be excluded because they are likely to experience a benefit no matter what treatment they receive or by ensuring that potential placebo responders are evenly allocated across treatment arms.

Hall notes that if the placebo response is influenced by certain brain signaling pathways, then it might also affect patients' responses to drugs that target those same pathways, and the magnitude of the drug effect might differ from one patient to another as a result of their genotype.

"These are novel hypotheses that, to our knowledge, have not yet been discussed in the scientific literature," she says. "This broader conception that points to more personalized medicine calls for additional research." Her group proposes including no-treatment controls in addition to placebo controls in some future clinical trials. "Our proposal to incorporate a formal placebo study into future clinical trials is innovative and could represent significant cost savings, leading to rapid access to knowledge of mechanisms involved in the placebo response across a wide variety of disease and drug regimens," Hall says.

A number of ethical issues must be considered if genetic profiles of placebo responders can be established. If high placebo responders are not included in clinical trials, this raises several important questions. For example, how will the drugs be labeled, and which patients will be approved for treatment in light of the fact that the drugs will have only been tested in placebo non-responders? Should physicians test for genetic placebo-response propensities and should patients be allowed to refuse permission to be tested? Should patients be told about their propensity to respond to placebos, and could patients refuse to know or refuse to have this designation in their medical records? Would physicians be able to ethically use this information and, if so, how? And of course, what if knowing one is a placebo responder affects one's placebo response?

This study was funded by the National Institutes of Health and the National Center for Complementary and Integrative Health.

Trends in Molecular Medicine, Hall et al.: "Genetics and the Placebo Effect: the Placebome" http://dx.doi.org/10.1016/j.molmed.2015.02.009

Most Popular Now

Pfizer announces positive top-line results from Ph…

Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational ...

Time-restricted eating reshapes gene expression th…

Numerous studies have shown health benefits of time-restricted eating including increase in life span in laboratory studies, making practices like intermittent fasting a ...

Incurable liver disease may prove curable

Research led by Associate Professor Duc Dong, Ph.D., has shown for the first time that the effects of Alagille syndrome, an incurable genetic disorder that affects the li...

Scientists develop a cancer vaccine to simultaneou…

Scientists are harnessing a new way to turn cancer cells into potent, anti-cancer agents. In the latest work from the lab of Khalid Shah, MS, PhD, at Brigham and Women’s ...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

COVID-19 vaccines, prior infection reduce transmis…

Vaccination and boosting, especially when recent, helped to limit the spread of COVID-19 in California prisons during the first Omicron wave, according to an analysis by ...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

Enzyme that protects against viruses could fuel ca…

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells, according to a ...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...